SCHEMBL16615929

SCHEMBL16615929

Cc1ncc(CNC(=O)c2ccc(CNC(=O)c3cc(F)cc(F)c3)cn2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 3/20 0.49
GRIN1 Q05586 2/20 0.49
SCD O00767 1/20 0.45
GRIN2B Q13224 1/20 0.45
MMP13 P45452 1/20 0.41
RET P07949 2/20 0.41
EGLN1 Q9GZT9 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
THRB P10828 1/20 0.40
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
AURKA O14965 1/20 0.39
CSF1R P07333 1/20 0.39
PRKAA2 P54646 1/20 0.39
KLKB1 P03952 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615798 0.91 HPGD (0.47) GRIN2AGRIN1SCDGRIN2BMMP13
SCHEMBL16598144 0.85 GRIN2A (0.60) GRIN2AGRIN1SCDGRIN2BSMN1; SMN2
SCHEMBL16615944 0.85 GRIN2A (0.59) GRIN2AGRIN1SCDGRIN2BCSF1R
SCHEMBL16615844 0.84 EPHX2 (0.51) GRIN2AGRIN1SMN1; SMN2POLBLMNA
SCHEMBL16598119 0.83 L3MBTL1 (0.41) MMP13EGLN1SMN1; SMN2THRBPOLB
SCHEMBL16615789 0.82 GRIN2A (0.53) GRIN2AGRIN1SCDGRIN2BMMP13
SCHEMBL16615837 0.80 VNN1 (0.48) GRIN2AGRIN1GAA
SCHEMBL16615818 0.80 GRIN2A (0.62) GRIN2AGRIN1SCDGRIN2BEGLN1
SCHEMBL16598092 0.80 GRIN2A (0.61) GRIN2AGRIN1SCDGRIN2BTP53
SCHEMBL16615794 0.79 GRIN2A (0.49) GRIN2AGRIN1GRIN2BTHRBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885SCD 4022/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885SCD 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.